HMOX1 and atherosclerosis: Indeed, adenoviral HO-1 overexpression via intracardiac administration, resulting in both aortic and liver overexpression, confers protection against atherosclerosis whereas tail vein administration, only resulting in hepatic but not aortic overexpression, does not (Juan et al., 2001).